Literature DB >> 23304048

Metastatic melanoma presenting as polymorphic ventricular tachycardia.

Jyoti Sharma1, Jonathan Matthew Brunson, Nada Memon, Aarif Y Khakoo.   

Abstract

A 41-year-old woman with metastatic melanoma was admitted to the hospital because of syncopal episodes, which had developed after the administration of an experimental chemotherapy agent that targeted Notch signaling, as part of a phase I clinical trial. Cardiac monitoring revealed recurrent episodes of polymorphic ventricular tachycardia correlating with the patient's syncope. Investigations into the cause of the arrhythmia led to the discovery of metastatic lesions within the left ventricular myocardium. In presenting this case of polymorphic ventricular tachycardia as the antemortem clinical manifestation of metastatic melanoma involving the heart, we discuss the importance of recognizing that cardiac metastases can manifest themselves as arrhythmias in patients with malignant melanoma who are undergoing active anticancer treatment.

Entities:  

Keywords:  Antineoplastic chemotherapy protocols/adverse effects; arrhythmias, cardiac/chemically induced/diagnosis/physiopathology/therapy; coronary disease/complications; heart neoplasms/pathology/secondary; melanoma/pathology; myocardium/pathology; receptors, notch/metabolism; recurrence/prevention & control; syncope/etiology; tachycardia, ventricular/chemically induced/etiology

Mesh:

Year:  2012        PMID: 23304048      PMCID: PMC3528232     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  22 in total

Review 1.  Clinical spectrum of ventricular tachycardia.

Authors:  M Akhtar
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

2.  Torsades de pointes: occurrence in myocardial ischaemia as a separate entity. Multiform ventricular tachycardia or not?

Authors:  H Zilcher; D Glogar; F Kaindl
Journal:  Eur Heart J       Date:  1980-02       Impact factor: 29.983

3.  Relation between QT and RR intervals in patients with bradyarrhythmias.

Authors:  S Ishida; N Takahashi; M Nakagawa; T Fujino; T Saikawa; M Ito
Journal:  Br Heart J       Date:  1995-08

Review 4.  Spiral wave activity: a possible common mechanism for polymorphic and monomorphic ventricular tachycardias.

Authors:  J M Davidenko
Journal:  J Cardiovasc Electrophysiol       Date:  1993-12

5.  Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.

Authors:  J S Economou; M Hoban; J D Lee; R Essner; S Swisher; W McBride; D B Hoon; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.

Authors:  G Stoter; S Aamdal; S Rodenhuis; F J Cleton; S Iacobelli; C R Franks; R Oskam; E Shiloni
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

Review 7.  Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II.

Authors:  S G Priori; J Barhanin; R N Hauer; W Haverkamp; H J Jongsma; A G Kleber; W J McKenna; D M Roden; Y Rudy; K Schwartz; P J Schwartz; J A Towbin; A M Wilde
Journal:  Circulation       Date:  1999-02-02       Impact factor: 29.690

8.  Cardiac metastases.

Authors:  E C Klatt; D R Heitz
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

9.  Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.

Authors:  R L White; D J Schwartzentruber; A Guleria; M P MacFarlane; D E White; E Tucker; S A Rosenberg
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

10.  Persistence of ventricular arrhythmia after resolution of occult myocarditis in children and young adults.

Authors:  R A Friedman; D L Kearney; J P Moak; A L Fenrich; J C Perry
Journal:  J Am Coll Cardiol       Date:  1994-09       Impact factor: 24.094

View more
  1 in total

1.  [Staging of cutaneous malignant melanoma by CT].

Authors:  J Hoffend
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.